Is the business good?
How good a business is OMCL?
Omnicell, Inc. earns 2.6% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
2.6%
Return on invested capital · cost of capital 9.0% · 6.4 points below what the capital costs: growth destroys value
- Operating margin
- 2.8%
Operating margin · Health Information Services median 2.3% · 12 months to Q1 2026
- Share count, year on year
- −1.4%
Share count, year on year · bought back, each share owns more of the company
- R&D as % of revenue
- 7.3%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | 4.0% |
| FY2021 | 7.9% |
| FY2022 | −0.18% |
| FY2023 | −3.0% |
| FY2024 | 0.03% |
| FY2025 | 0.44% |
Details›
- Gross margin12 months to Q1 2026
- 44%
- Operating margin12 months to Q1 2026
- 2.8%
- Net margin12 months to Q1 2026
- 1.7%
- Free cash flow margin
- 9.3%
- R&D as % of revenue
- 7.3%
- Revenue, trailing twelve months
- $1.23B
- Free cash flow, trailing twelve months
- $114M
- Net income, trailing twelve months
- $20M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 2.6%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.
Health Information Services
Ranks #11 of 14 by Smart Score